Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521436 | 0.94 | EGFR (0.43) | L3MBTL3L3MBTL1EGFRTP53BP1MBTD1 | |
| SCHEMBL14180538 | 0.87 | TLR9 (0.48) | ALKTLR9TLR8TLR7 | |
| SCHEMBL10206202 | 0.87 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1EGFRTP53BP1MBTD1 | |
| SCHEMBL521798 | 0.85 | MEN1 (0.41) | EGFRPLK1 | |
| SCHEMBL311282 | 0.85 | TGFBR1 (0.41) | L3MBTL3L3MBTL1EGFRTP53BP1MBTD1 | |
| SCHEMBL520521 | 0.85 | ALK (0.48) | L3MBTL3L3MBTL1EGFRALKINSR | |
| SCHEMBL2234370 | 0.84 | GAA (0.47) | ALK | |
| SCHEMBL520836 | 0.84 | L3MBTL1 (0.57) | L3MBTL3L3MBTL1EGFRTP53BP1MBTD1 | |
| SCHEMBL309548 | 0.83 | L3MBTL1 (0.55) | L3MBTL3L3MBTL1TP53BP1MBTD1 | |
| SCHEMBL13981638 | 0.83 | L3MBTL1 (0.55) | L3MBTL3L3MBTL1TP53BP1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | L3MBTL3 3289/4885L3MBTL1 2484/4885EGFR 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.